Table 1.

BCPs inhibitors in clinical trials

Drug	Interventions	Phase	Conditions	NCT Number	Status
Molibresib	combination with entinostat	I	lymphoma, solid tumors	NCT03925428	withdrawn
	combination with cisplatin/etoposide	I/II	NUT Carcinoma	NCT04116359	withdrawn
	combination with fulvestrant	I	neoplasms	NCT02964507	completed
	monotherapy	I	NMC	NCT01587703	completed
	crossover assignment (rifampin/itraconazole)	I	neoplasms	NCT02706535	completed
	monotherapy		NMC	NCT03702036	no longer available
	combinationwith androgen deprivation therapy	I	CRPC	NCT03150056	terminated
	combination with trametinib	II	solid tumors	NCT03266159	withdrawn
	monotherapy	II	neoplasms	NCT01943851	completed
Birabresib	monotherapy	I	AML, DLBCL	NCT02698189	terminated-limited efficacy
	monotherapy	I	NMC, TNBC, NSCLC, CRPC	NCT02698176	Terminated-limited efficacy
	monotherapy	I	NMC, TNBC, NSCLC, CRPC	NCT02259114	completed
	monotherapy	I	AML, DLBCL, ALL, MM	NCT01713582	completed
	monotherapy	II	GBM	NCT02296476	terminated
	combination with vidaza	I/II	AML	NCT02303782	withdrawn
CPI-0610	monotherapy	I	MM	NCT02157636	completed
	monotherapy	I	lymphoma	NCT01949883	completed
	monotherapy	I	advanced malignancies	NCT05391022	recruiting
	combination with ruxolitinib	I/II	myelofibrosis	NCT02158858	active, not recruiting
	monotherapy	II	MPNST	NCT02986919	withdrawn
	combination with ruxolitinib	III	myelofibrosis	NCT04603495	recruiting
PLX51107	monotherapy	I/II	GVHD	NCT04910152	recruiting
	combination with azacitidine	I	AML, MDS	NCT04022785	recruiting
	monotherapy	I	advanced malignancies	NCT02683395	terminated
ODM-207	monotherapy	I/II	solid tumors	NCT03035591	completed
29	monotherapy	I/II	advanced malignancies	NCT02431260	terminated-PK variability
	monotherapy		metastatic RCC	NCT03896815	no longer available
CC-90010	monotherapy	I	astrocytoma, glioblastoma	NCT04047303	active, not recruiting
	monotherapy	I	NHL, solid tumors	NCT03220347	active, not recruiting
	combination with temozolomide	I	glioblastoma	NCT04324840	recruiting
	combination with BMS-986158	I	pediatric cancer	NCT03936465	recruiting
BMS-986158	monotherapy or combination therapy	I/II	myelofibrosis	NCT04817007	recruiting
	monotherapy or combination therapy	I/II	advanced tumors	NCT02419417	completed
	combination therapy	I/II	MM	NCT05372354	recruiting
ABBV-075	monotherapy or combination with venetoclax	I	cancers	NCT02391480	completed
	monotherapy or combination therapy	I	myelofibrosis	NCT04480086	active, not recruiting
BI 894,999	monotherapy	I	advanced malignancies	NCT02516553	completed
RVX208	monotherapy	I/II	fabry disease	NCT03228940	unknown
	monotherapy	I/II	dyslipidemia, atherosclerosis	NCT00768274	completed
	monotherapy	II	atherosclerosis, CAD	NCT01058018	completed
	monotherapy	II	CAD, dyslipidemia	NCT01423188	completed
	monotherapy	II	diabetes	NCT01728467	completed
	combination with rosuvastatin/atorvastatin	II	dyslipidemia, CAD	NCT01863225	terminated
	combination with atorvastatin/ rosuvastatin	III	diabetes, CAD	NCT02586155	completed
ABBV-744	monotherapy	I	AML	NCT03360006	terminated
	monotherapy or combination therapy	I	myelofibrosis	NCT04454658	recruiting
AZD5153	monotherapy or combination with olaparib	I	solid tumors	NCT03205176	completed
	combination with acalabrutinib	I	NHL	NCT03527147	completed
CCS1477	monotherapy or combination therapy	II	advanced tumours	NCT03568656	recruiting
	monotherapy or combination therapy	I/II	haematological malignancy	NCT04068597	recruiting

Sourced from https://clinicaltrials.gov/ (March 2023)

Abbreviations used in the table: ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, CAD Coronary artery disease, CRPC Castration-resistant prostate cancer, DLBCL Diffuse large B-cell lymphoma, GBM Glioblastoma multiforme, GVHD Graft versus host disease, MDS Myelodysplastic syndrome, MM Multiple myeloma, MPNST Malignant Peripheral Nerve Sheath Tumors, NHL Non-Hodgkin’s lymphoma, NMC NUT midline Carcinoma, NSCLC Non-small cell lung cancer, RCC Renal cell carcinoma, SCLC Small cell lung cancer, TNBC Triple negative breast cancer